This genome-wide association study meta-analysis evaluates whether differences in risk of in situ melanoma and invasive melanoma are heritable.
Risultati per: Raccomandazioni Melanoma per pazienti e cittadini
Questo è quello che abbiamo trovato per te
Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy: a phase 2 multicentre study
Objective
This study evaluates the safety/efficacy of sabatolimab plus spartalizumab in patients with melanoma or non-small cell lung cancer (NSCLC).
Design, setting and participants
This is a phase 1–1b/2, open-label, multinational, multicentre study of patients with advanced/metastatic melanoma or NSCLC with ≥1 measurable lesion.
Interventions
Patients were given sabatolimab 800 mg every 4 weeks plus spartalizumab 400 mg every 4 weeks until unacceptable toxicity, disease progression and/or treatment discontinuation.
Outcome measures
The phase 2 primary outcome measure was overall response rate and secondary objectives included evaluation of the safety, tolerability, efficacy and pharmacokinetics of sabatolimab in combination with spartalizumab.
Results
33 patients (melanoma n=16, NSCLC n=17) received sabatolimab plus spartalizumab. 31 (94%) experienced ≥1 adverse event (AE); 15 (46%) experienced grade 3/4 events. The most frequent grade ≥3 AEs for NSCLC were anaemia, dyspnoea and pneumonia (each n=2, 12%); for patients with melanoma, the most frequent grade ≥3 AEs were physical health deterioration, hypokalaemia, hypophosphataemia, pathological fracture and tumour invasion (each n=1; 6%). One (3%) patient discontinued treatment due to AE. Stable disease was seen in three patients with melanoma (19%) and six patients with NSCLC (35%). Median progression-free survival was 1.8 (90% CI 1.7 to 1.9) and 1.7 (90% CI 1.1 to 3.4) months for patients with melanoma and NSCLC, respectively. Patients with stable disease had higher expression levels of CD8, LAG3, programmed death-ligand 1 and anti-T-cell immunoglobulin and mucin-domain containing-3 at baseline. The pharmacokinetics profile of sabatolimab was consistent with the phase 1 study.
Conclusions
Sabatolimab plus spartalizumab was well tolerated in patients with advanced/metastatic melanoma or NSCLC who had progressed following antiprogrammed death-1/antiprogrammed death-ligand 1 treatment. Limited antitumour activity was observed. The tolerability of sabatolimab administration supports the potential to explore treatment with sabatolimab in various combination regimens and across a spectrum of tumour types.
Trial registration number
NCT02608268.
Strategia generale per il trattamento dei pazienti con ipertensione
Raccomandazioni e utilizzo dei diversi metodi per la misurazione della PA (Pressione Arteriosa) – Ipertensione
Gestione dei pazienti con malattia coronarica cronica: linea guida
Recurrence Rate of Small Melanoma in Situ on Low-Risk Sites With 5-mm Excisional Margin
This case series investigates the recurrence rate of melanoma in situ treated with a 5-mm margin in low-risk body sites.
Recurrence Rate of Melanoma In Situ Excised With a 5-mm Excisional Margin
The recommendations for treating invasive melanoma have evolved dramatically during the past century. The surgical practices of radically wide margins and amputations were abandoned when evidence from randomized clinical trials (RCTs) showed that surgical margins as narrow as 1 cm were safe for most melanomas. In contrast, the recommendations for surgical margins for melanoma in situ (MIS) are not based on RCTs and exist with some controversy. The earliest recommendations of a 5-mm surgical margin for MIS was suggested by the National Institutes of Health by a panel of dermatologists in 1991 based on their experience rather than scientific evidence, and this became the recommended excision margin adopted by many national and international groups writing clinical guidelines. At the same time, the experience of Mohs surgeons and others looking carefully at the width of surgical margins necessary to achieve negative histologic margins led to a different conclusion. Multiple studies from various institutions showed that MIS often extends beyond a 5-mm clinical margin, and wider margins were necessary to avoid local recurrence and tumor progression. Although no RCTs were performed to my knowledge, the preponderance of evidence from these sources came to the same conclusion that margins wider than 5 mm for MIS are necessary to provide negative histologic margins in 97% of real-world lesions of MIS. However, the controversy continued about surgical margins for subgroups of MIS based on histology (MIS vs lentigo maligna), location (head and neck vs trunk and extremity), and other clinical parameters. Today, most clinical guidelines recommend a range of margins of 0.5 to 1 cm for all MIS, noting that the goal of excision is negative histologic margins.
Longitudinal gut microbiome shifts correlate with clinical outcomes of immune checkpoint inhibitors-treated melanoma: time for microbial biomarkers in oncology?
Lo psiconcologo aiuta, per il 71% dei pazienti è molto utile il supporto online
Ma nell’84% dei casi lo specialista non è presente nei centri
Nasce Pronto Ail Roma, servizio telefonico pazienti ematologici
Darà informazioni su diritti e servizi offerti dall’Associazione
Infermieri,soddisfatti 9 pazienti su 10 per assistenza domicilio
Valutazione media di 9,3 per gli infermieri attivi nelle case
Il 65% dei pazienti utilizzerebbe una terapia digitale
PoliMi, l’IA rivoluzionerà medicina personalizzata entro 5 anni
Identificato il meccanismo che impedisce l’efficacia delle terapie contro il melanoma
Dual Checkpoint Inhibition in Melanoma With ≥1% PD-L1—Time to Reassess the Evidence
This Viewpoint discusses use of anti–PD-1 monotherapy as the primary treatment option for patients with treatment-naive metastatic melanoma staining positive for PD-L1 over dual checkpoint inhibition therapy.
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
New England Journal of Medicine, Ahead of Print.
Sanità, liste d’attesa: dal salta coda al ticket per chi non si presenta, ecco cosa cambia per i pazienti
Il decreto garantisce che ogni prestazione sia assicurata nei tempi previsti dalle prioirità indicate in ricetta. Ma ci sono anche doveri per i cittadini